Cancer Genetics and Epigenetics 2024, Vol.12, No.2, 97-105 http://medscipublisher.com/index.php/cge 105 McGrath S., Christidis D., Perera M., Hong S.K., Manning T., Vela I., and Lawrentschuk N., 2016, Prostate cancer biomarkers: are we hitting the mark?, Prostate International, 4(4): 130-135. https://doi.org/10.1016/j.prnil.2016.07.002 Meng L., Li Y., Ren J., Shi T., Men J., and Chang C., 2019, Early stage biomarkers screening of prostate cancer based on weighted gene coexpression network analysis, DNA and Cell Biology, 38(5): 468-475. https://doi.org/10.1089/dna.2018.4406 Morrison G.J., and Goldkorn A., 2018, Development and application of liquid biopsies in metastatic prostate cancer, Current oncology reports, 20: 1-10. https://doi.org/10.1007/s11912-018-0683-0 Mosele F., Remon J., Mateo J., Westphalen C.B., Barlesi F., Lolkema M.P., Normanno N., Scarpa A., Robson M., Meric-Bernstam F., Wagle N., Stenzinger A., Bonastre J., Bayle A., Michiels S., Bièche I., Rouleau E., Jezdic S., Douillard J., Reis-Filho J., Dienstmann R., and André F., 2020, Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group, Annals of Oncology, 31(11): 1491-1505. https://doi.org/10.1016/j.annonc.2020.07.014 Na R., Zheng S.L., Han M., Yu H., Jiang D., Shah S., Ewing C., Zhang L., Novakovic K., Petkewicz J., Gulukota K., Helseth D., Quinn M., Humphries E., Wiley K., Isaacs S., Wu Y., Liu X., Zhang N., Wang C., Khandekar J., Hulick P., Shevrin D., Cooney K., Shen Z., Partin A., Carter H., Carducci M., Eisenberger M., Denmeade S., McGuire M., Walsh P., Helfand B., Brendler C., Ding Q., Xu J., Isaacs W., and Isaacs W.B., 2017, Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death, European Urology, 71(5): 740-747. https://doi.org/10.1016/S1569-9056(17)30541-9 Nam R.K., Zhang W.W., Trachtenberg J., Seth A., Klotz L.H., Stanimirovic A., Punnen S., Venkateswaran V., Toi A., Loblaw D., Sugar L., Siminovitch K., and Narod S.A., 2009, Utility of incorporating genetic variants for the early detection of prostate cancer, Clinical Cancer Research, 15(5): 1787-1793. https://doi.org/10.1158/1078-0432.CCR-08-1593 Nevo A., Navaratnam A., and Andrews P., 2020, Prostate cancer and the role of biomarkers, Abdominal Radiology, 45: 2120-2132. https://doi.org/10.1007/s00261-019-02305-8 Ni Raghallaigh, H., and Eeles R., 2022, Genetic predisposition to prostate cancer: an update. Familial Cancer, 21(1): 101-114. https://doi.org/10.1007/s10689-021-00227-3 Oellerich, M., Schütz, E., Beck, J., Kanzow, P., Plowman, P. N., Weiss, G. J., and Walson, P. D., 2017, Using circulating cell-free DNA to monitor personalized cancer therapy. Critical reviews in clinical laboratory sciences, 54(3): 205-218. https://doi.org/10.1080/10408363.2017.1299683 Tukachinsky H., Madison R.W., Chung J.H., Gjoerup O.V., Severson E.A., Dennis L., Fendler B., Morley S., Zhong L., Graf R., Ross J., Alexander B., Abida W., Chowdhury S., Ryan C., Fizazi K., Golsorkhi T., Watkins S., Simmons A., Loehr A., Venstrom J., and Oxnard G.R., 2021, Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms, Clinical Cancer Research, 27(11): 3094-3105. https://doi.org/10.1158/1078-0432.CCR-20-4805 Woodward E.R., Lalloo F., Forde C., Pugh S., Burghel G.J., Schlecht H., Harkness E., Howell A., Howell S., Gandhi A., and Evans D.G., 2024, Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c. 1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400, Journal of Medical Genetics, 61(4): 385-391. https://doi.org/10.1136/jmg-2023-109671 Zhen J.T., Syed J., Nguyen K.A., Leapman M.S., Agarwal N., Brierley K., Llor X., Hofstatter E., and Shuch B., 2018, Genetic testing for hereditary prostate cancer: current status and limitations, Cancer, 124(15): 3105-3117. https://doi.org/10.1002/cncr.31316
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==